Larazotide acetate (AT-1001)
Gut · Tight junction regulator
Tier D+
What this is
Failed Ph3 primary endpoint in celiac disease 2022 despite promising Ph2b. Some use in 'leaky gut' biohacker protocols despite the failed trial. Mechanism is legitimate but real-world benefit unproven.
Mechanism
Octapeptide zonulin antagonist; tightens intestinal tight junctions; reduces intestinal permeability; developed for celiac disease adjunct to GFD
Dose & route
0.5 mg PO 3x/day in trials
Citations
- https://pubmed.ncbi.nlm.nih.gov/33007414/
- https://investors.9meters.com/news-releases/news-release-details/9-meters-biopharma-announces-topline-results-phase-3-ccesti
- https://pubmed.ncbi.nlm.nih.gov/34665306/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.